Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPARγ-independent signaling pathways

Du Hyong Cho, Yoon Jung Choi, Sangmee Ahn Jo, Inho Jo

Research output: Contribution to journalArticlepeer-review

151 Scopus citations

Abstract

Recently, peroxisome proliferator-activated receptor γ (PPARγ) ligands have been reported to increase endothelial NO, but the signaling mechanisms involved are unknown. Using troglitazone, a PPARγ ligand known as an antidiabetic compound, we investigated the molecular mechanism of its effect on NO production in bovine aortic endothelial cells. Troglitazone increased endothelial NO production in a dose- and time-dependent manner with no alteration in endothelial nitric-oxide synthase (eNOS) expression. The maximal increase (∼3.1-fold) was achieved with 20 μM troglitazone treatment for 12 h, and this increase was accompanied by increases in the expression of vascular endothelial growth factor (VEGF) and its receptor, KDR/Flk-1, and in Akt phosphorylation. Analysis with antibodies specific for each phosphorylated site demonstrated that troglitazone (20 μM treatment for 12 h) significantly increased both the phosphorylation of Ser1179 of eNOS (eNOS-Ser1179) and the dephosphorylation of eNOS-Ser 116 but did not alter eNOS-Thr497 phosphorylation. Treatment with anti-VEGF antibody to scavenge the increased VEGF induced by troglitazone partially inhibited troglitazone-stimulated NO production. This was accompanied by the attenuation of troglitazone-stimulated increases in the phosphorylation of Akt and eNOS-Ser1179 with no alteration in eNOS-Ser116 dephosphorylation. We also found that bisphenol A diglycidyl ether, a PPARγ antagonist, partially inhibited troglitazone-stimulated NO production with a concomitant reduction in VEGF-KDR/Flk-1-Akt-mediated eNOS-Ser1179 phosphorylation but with no alteration in eNOS-Ser116 dephosphorylation induced by troglitazone. Taken together, our results demonstrate that prolonged treatment with troglitazone increases endothelial NO production by at least two independent signaling pathways: PPARγ-dependent, VEGF-KDR/Flk-1-Akt-mediated eNOS-Ser1179 phosphorylation and PPARγ-independent, eNOS-Ser116 dephosphorylation.

Original languageEnglish
Pages (from-to)2499-2506
Number of pages8
JournalJournal of Biological Chemistry
Volume279
Issue number4
DOIs
StatePublished - 23 Jan 2004

Fingerprint

Dive into the research topics of 'Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: Evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ-dependent and PPARγ-independent signaling pathways'. Together they form a unique fingerprint.

Cite this